- Home
- DRUG vs FT Comparison
DRUG vs FT Comparison
Compare DRUG & FT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- FT
- Stock Information
- Founded
- DRUG 2019
- FT 1988
- Country
- DRUG United States
- FT United States
- Employees
- DRUG N/A
- FT N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- FT Trusts Except Educational Religious and Charitable
- Sector
- DRUG Health Care
- FT Finance
- Exchange
- DRUG Nasdaq
- FT Nasdaq
- Market Cap
- DRUG 199.7M
- FT 192.5M
- IPO Year
- DRUG N/A
- FT N/A
- Fundamental
- Price
- DRUG $25.41
- FT $7.72
- Analyst Decision
- DRUG Strong Buy
- FT
- Analyst Count
- DRUG 7
- FT 0
- Target Price
- DRUG $83.25
- FT N/A
- AVG Volume (30 Days)
- DRUG 60.0K
- FT 63.0K
- Earning Date
- DRUG 08-13-2025
- FT 01-01-0001
- Dividend Yield
- DRUG N/A
- FT 7.85%
- EPS Growth
- DRUG N/A
- FT N/A
- EPS
- DRUG N/A
- FT N/A
- Revenue
- DRUG N/A
- FT N/A
- Revenue This Year
- DRUG N/A
- FT N/A
- Revenue Next Year
- DRUG N/A
- FT N/A
- P/E Ratio
- DRUG N/A
- FT N/A
- Revenue Growth
- DRUG N/A
- FT N/A
- 52 Week Low
- DRUG $0.93
- FT $5.97
- 52 Week High
- DRUG $79.02
- FT $7.23
- Technical
- Relative Strength Index (RSI)
- DRUG 43.34
- FT 61.92
- Support Level
- DRUG $26.09
- FT $7.45
- Resistance Level
- DRUG $27.50
- FT $7.77
- Average True Range (ATR)
- DRUG 1.95
- FT 0.09
- MACD
- DRUG 0.12
- FT 0.01
- Stochastic Oscillator
- DRUG 44.62
- FT 77.94
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About FT Franklin Universal Trust
Franklin Universal Trust is a closed-end management investment company. Its primary investment objective is to provide high, current income consistent with the preservation of capital. Its secondary objective is the growth of income through dividend increases and capital appreciation. The fund invests in two asset classes being the high yield bonds and utility stocks.